Skip to content
    The Column Group logo

    The Column Group

    San Francisco, California, United StatesFounded 2007
    www.thecolumngroup.comLinkedIn
    Biotech & Life Sciences

    The Column Group (TCG) is a science-driven venture capital firm based in San Francisco that partners with world-class scientists and entrepreneurs to build transformative drug discovery and development companies. Founded in 2007 by Peter Svennilson, the firm employs an edge-to-edge investment model supporting companies from inception through exit.

    72% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $82.6M (across 80 rounds with reported amounts).

    Find people at The Column Group on Goldilocks AI

    Portfolio

    53

    Fund Size

    $615M

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    Peter Svennilson

    Peter Svennilson

    Founder / Managing Partner

    Tim Kutzkey, PhD

    Tim Kutzkey, PhD

    Managing Partner

    Arnav Mehta, MD, PhD

    Arnav Mehta, MD, PhD

    Venture Partner

    Carla Daniel

    Carla Daniel

    Partner & Chief People Officer

    Charles Sawyers, MD

    Charles Sawyers, MD

    Science Partner

    Charles Zuker, PhD

    Charles Zuker, PhD

    Science Partner

    Craig Parker

    Craig Parker

    Venture Partner

    David V. Goeddel, PhD

    David V. Goeddel, PhD

    Partner Emeritus

    Helen Hobbs, PhD

    Helen Hobbs, PhD

    Science Partner

    Huda Y. Zoghbi, MD

    Huda Y. Zoghbi, MD

    Science Partner

    Hui Tian, PhD

    Hui Tian, PhD

    Partner

    James Evangelista

    James Evangelista

    Partner & Chief Financial Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    88 investments
    CompanyRoundAmountDate
    AAtavistikSeries B—Mar 2026
    Atavistik Bio logoAtavistik BioSeries B$120MDec 2025
    Tr1X logoTr1XUnknown$50MOct 2025
    Nilo Therapeutics logoNilo TherapeuticsSeries A$101MOct 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Surrozen logoSurrozenSeries D$175MMar 2025
    Eikon Therapeutics, Inc. logoEikon Therapeutics, Inc.Series D$350.7MFeb 2025
    AA2 Biotherapeutics, Inc.Series C$80MJan 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    RAPT Therapeutics logoRAPT TherapeuticsSeries D$150MDec 2024
    Accent Therapeutics logoAccent TherapeuticsSeries C$75MJan 2024
    Tr1X logoTr1XSeries A$75MJan 2024
    Remix Therapeutics logoRemix TherapeuticsSeries C$60MJan 2024
    Nura Bio logoNura BioSeries A—Jan 2024
    KKenai TherapeuticsSeries A$82MJan 2024
    Neurona logoNeuronaUnknown$120MJan 2024
    Gritstone Oncology logoGritstone OncologySeries B$92.7MJan 2024
    Kimia Therapeutics logoKimia TherapeuticsSeries A$55MDec 2023
    Carmot Therapeutics logoCarmot TherapeuticsSeries E$150MMay 2023
    Hexagon Bio logoHexagon BioSeries B$77.3MFeb 2023
    SSynthekine, Inc.Series C$100MJan 2023
    Kimia logoKimiaSeries A$55MJan 2023
    Cajal Neuroscience logoCajal NeuroscienceSeries A$96MNov 2022
    Remix Therapeutics logoRemix TherapeuticsSeries B$70MMay 2022
    Plexium logoPlexiumGrowth$102MFeb 2022
    Page 1 of 4

    Top Co-Investors

    Euclidean Capital18 shared
    Samsara BioCapital17 shared
    Alexandria Venture Investments15 shared
    Nextech Invest Ltd.15 shared
    Foresite Capital14 shared
    RA Capital Management13 shared
    GV11 shared
    Casdin Capital11 shared
    Lux Capital10 shared
    Pivotal Life Sciences8 shared
    Celgene7 shared
    Atlas Venture7 shared
    Horizons Ventures6 shared
    Novartis Venture Fund6 shared
    Bristol Myers Squibb6 shared
    UC Investments5 shared
    Willett Advisors5 shared
    Redmile Group5 shared
    Third Rock Ventures5 shared
    Schroders Capital4 shared

    Last updated: 7 October 2026